Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - F-star Therapeutics, Inc. | d192920dex312.htm |
| EX-31.1 - EX-31.1 - F-star Therapeutics, Inc. | d192920dex311.htm |
| 10-Q - 10-Q - F-star Therapeutics, Inc. | d192920d10q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Spring Bank Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
| (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| Date: June 15, 2016 | By: | /s/ Martin Driscoll | ||||
| Martin Driscoll Chief Executive officer | ||||||
| (Principal Executive Officer) |
| By: | /s/ Jonathan Freve | |||||
| Jonathan Freve Chief Financial Officer, Treasurer and Secretary | ||||||
| (Principal Financial and Accounting Officer) |